Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Durvalumab Alone and Durvalumab Plus Tremelimumab Versus Chemotherapy in Previously Untreated Patients With Unresectable, Locally Advanced or Metastatic Urothelial Carcinoma (DANUBE): A Randomised, Open-Label, Multicentre, Phase 3 TrialLancet Oncol 2020 Sep 21;[EPub Ahead of Print], T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, DP Petrylak, O Ogawa, SH Park, JL Lee, U De Giorgi, M Bögemann, A Bamias, BJ Eigl, H Gurney, SD Mukherjee, Y Fradet, I Skoneczna, M Tsiatas, A Novikov, C Suárez, AP Fay, I Duran, A Necchi, S Wildsmith, P He, N Angra, AK Gupta, W Levin, J Bellmunt
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.